PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron - Related Studies

PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron

This study has been terminated.

Study NCT00037882. Last updated on June 23, 2005. Information provided by M.D. Anderson Cancer Center

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Additional conditions recognized in this trial
		Leukemia
		Leukemia, Myelogenous, Chronic, BCR-ABL Positive
		Leukemia, Myeloid

2	More general conditions related to this trial
		Bone Marrow Diseases
		Hematologic Diseases
		Myeloproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

3	Interventions listed in this trial
		PEG-Intron

4	Additional drug interventions recognized in this trial
		Interferon-alpha
		Interferons
		Peginterferon alfa-2b

5	More general drug interventions related to this trial
		Anti-Infective Agents
		Antineoplastic Agents
		Antiviral Agents
		Immunologic Factors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		M.D. Anderson Cancer Center
		Schering-Plough